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licenses/by/4.0/).Abstract Background: The De-ESCALaTE HPV trial confirmed the dominance of cisplatin
over cetuximab for tumour control in patients with human papillomavirus (HPV)-positive
oropharyngeal squamous cell carcinoma (OPSCC). Here, we present the analysis of health-
related quality of life (HRQoL), resource use, and health care costs in the trial, as well as com-
plete 2-year survival and recurrence.
Materials and methods: Resource use and HRQoL data were collected at intervals from the
baseline to 24 months post treatment (PT). Health care costs were estimated using UK-
based unit costs. Missing data were imputed. Differences in mean EQ-5D-5L utility index
and adjusted cumulative quality-adjusted life years (QALYs) were compared using the Wil-
coxon signed-rank test and linear regression, respectively. Mean resource usage and costs were
compared through two-sample t-tests.
Results: 334 patients were randomised to cisplatin (n Z 166) or cetuximab (n Z 168). Two-
year overall survival (97$5% vs 90$0%, HR: 3.268 [95% CI 1$451 to 7$359], p Z 0$0251)
and recurrence rates (6$4% vs 16$0%, HR: 2$67 [1$38 to 5$15]; p Z 0$0024) favoured
cisplatin. No significant differences in EQ-5D-5L utility scores were detected at any time point.omics Research Centre, Nuffield Department of Population Health, University of Oxford, Richard Doll
on, Roosevelt Drive, Oxford, OX3 7LF, UK.
x.ac.uk (A.M. Gray).
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D.A. Jones et al. / European Journal of Cancer 124 (2020) 178e185 179At 24 months PT, mean difference was 0$107 QALYs in favour of cisplatin (95% CI: 0$186 to
0$029, pZ 0$007) driven by the mortality difference. Health care costs were similar across all
categories except the procurement cost and delivery of the systemic agent, with cetuximab
significantly more expensive than cisplatin (£7779 [P < 0.001]). Consequently, total costs at
24 months PT averaged £13517 (SE: £345) per patient for cisplatin and £21064 (SE: £400)
for cetuximab (mean difference £7547 [95% CI: £6512 to £8582]).
Conclusions: Cisplatin chemoradiotherapy provided more QALYs and was less costly than ce-
tuximab bioradiotherapy, remaining standard of care for nonsurgical treatment of HPV-
positive OPSCC.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The incidence of oropharyngeal squamous cell carci-
noma (OPSCC) is rising in many developed countries,
driven principally by increasing infection rates of
oncogenic human papillomavirus (HPV) [1,2]. HPV-
positive OPSCC represents a distinct disease entity to
its HPV-negative counterpart. While the latter is typi-
cally induced by excessive smoking and/or alcohol
consumption, HPV-positive patients are often younger
and healthier, characterised by favourable prognosis
with half the risk of death [3].
Nevertheless, current treatment practices do not
differentiate between disease types, and are associated
with acute and late toxicities. This morbidity is of
particular concern for HPV-positive patients given the
favourable long-term survival rates and young age of
diagnosis, leading many patients to live with poor
health-related quality of life (HRQoL) over extended
periods. Management of treatment-related sequelae also
imposes considerable additional costs on the health care
system, as well as privately on the individual.
Consequently, there has been a refocusing of the
therapeutic paradigm for HPV-positive OPSCC towards
de-escalation, which ideally reduces treatment-related
toxicities without compromising tumour control.
Cetuximab, a monoclonal antibody against epidermal
growth factor receptor, is one of the first treatments
under investigation for de-escalation [4]. The potential
clinical benefit of cetuximab for head and neck squa-
mous cell carcinoma was first demonstrated in a rand-
omised controlled trial of radiotherapy versus
radiotherapy plus cetuximab [5,6]. This led to the
investigation of its comparative effectiveness versus
standard care cisplatinebased chemoradiotherapy for
HPV-positive OPSCC in the De-ESCALaTE HPV
(ISRCTN33522080) international open-label rando-
mised controlled phase III trial [7].
De-ESCALaTE HPV recently reported expedited
results of their comparison of radiotherapy plus con-
current cisplatin or cetuximab, with the primary
outcome of difference in severe (grade 3e5) toxicityevents. Compared with the standard cisplatin regimen,
cetuximab showed no benefit in terms of reduced
toxicity, but significant detriment in terms of tumour
control [7]. These results were in line with those from the
multicentre NRG Oncology RTOG 1016 noninferiority
trial [8]. The cisplatin regimen did result, however, in
significantly more serious adverse events (SAEs) [7].
A prespecified secondary objective of De-ESCALaTE
HPV was to compare medical resource use, costs, and
HRQoL in the two study arms, and we now report this
analysis. Although the survival results were unfav-
ourable to cetuximab, the trial does provide reliable
information on medical resource use, related costs, and
HRQoL as measured by the generic multiattribute EQ-
5D-5L utility instrument after standard care cisplatin
and radiotherapy in this population. With many other
de-escalation treatments strategies under investigation,
such data are vital to help evaluate these strategies
against current standard care. We also report completed
estimates from the trial of 2-year overall survival and
time to recurrence.2. Materials and methods
2.1. Study
Full details of the De-ESCALaTE HPV trial can be
found in the previously published results paper [7].
Briefly, eligible patients were aged 18 years or older with
low-risk HPV-positive advanced OPSCC, defined ac-
cording to the Ang classification [3] as nonsmokers or
smokers with a lifetime history of <10 pack-years, with
positive p16 immunohistochemistry. Patients were
recruited from treatment centres in Ireland (n Z 1), the
Netherlands (n Z 1), and the UK (n Z 30), and
randomly assigned (1:1) through a minimisation algo-
rithm including centre, tumour stage (TNM7: T1eT2 vs
T3eT4), nodal stage (N0e1 vs N2e3), radiotherapy site
(unilateral; bilateral), and planned gastrostomy inser-
tion before treatment. Therapy consisted of radio-
therapy (70 Gy in 35 fractions), with either intravenous
D.A. Jones et al. / European Journal of Cancer 124 (2020) 178e185180cisplatin (100 mg/m2 on days 1, 22, and 43 of radio-
therapy) or intravenous cetuximab (400 mg/m2 initial
dose followed by seven weekly infusions of 250 mg/m2).
Patients were followed up for a minimum of two years
with monthly examinations at the clinic in the first year,
and every two months in the second year, in line with
normal clinical practice to detect recurrence early.
2.2. Health care resource use and quality of life data
collection, and attribution of costs
Throughout the trial, data on resource use were
collected by means of case report forms (CRFs) and
resource use questionnaires (RUQs) which were adapted
from RUQs used in several previous trials and found to
have high completion and low error rates [9e11]. Dur-
ing treatment, CRFs collected information on the
administration of radiotherapy and radiosensitising
agent, including whether radiotherapy was completed,
number of chemo/biotherapy cycles received, cycle dose,
and for the cisplatin arm any switches to carboplatin.
Ancillary items given during chemo/biotherapy such as
hydration and anti-emetics were obtained from pre-
specified centre regimen documents. Follow-up CRFs
recorded details of all hospital admissions, as well as
contacts with the consultant, and any imaging per-
formed. The RUQs were given at the baseline, end of
treatment (on average two months after baseline), and 6,
12, and 24 months post treatment (PT), with patients
asked to recall their use of health care services over the
intervening period. Each questionnaire contained items
on hospital-based care including inpatient stays, day
centre and outpatient clinic visits, accident and emer-
gency contacts, and convalescent and nursing home
stays. It also contained items on primary and commu-
nity care activities such as GP, nurse, social worker, and
therapist visits. There were overlaps between the data
collected in the CRFs and RUQs concerning hospital-
isations, imaging, and consultant visits, and a summary
of the approach taken to reconcile these can be found in
the online Appendix.
Unit costs associated with resource usage were ob-
tained from UK-based sources including the Depart-
ment of Health and Social Care’s drugs and
pharmaceutical electronic market information tool, the
British National Formulary, National Health
Service reference costs, and the Unit Costs of Health
and Social Care [12e15]. Details of unit costs and their
sources are provided in the online Appendix.
HRQoL was assessed using one of the most widely
used generic preference-based measures, the EQ-5D-5L
questionnaire, which was administered at the baseline,
end of treatment, and 3, 6, 12, and 24 months PT [16].
The EQ-5D-5L questionnaire covers five health do-
mains: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Patients then identify their
current health status for each domain as one of fivelevels: no problems, slight problems, moderate prob-
lems, severe problems, and extreme, leading to 3125
possible health states. Each health state can be attrib-
uted a utility index score using a valuation set (also
known as tariff), which results in a preference-based
score ranging from <0 (states worse than dead) to 1
(full health), with dead anchored at 0.
2.3. Statistical analysis
The primary analysis was performed on all randomised
patients under the intention-to-treat principle. A sec-
ondary analysis was performed on the per-protocol
population, excluding patients who withdrew or who
had major protocol violations as assessed by the inde-
pendent trial monitoring team. Descriptive statistics of
the trial population by treatment arm were derived,
including means, medians, standard deviations, and
interquartile ranges as appropriate. 2-year overall sur-
vival and time to recurrence were estimated, for the
intention-to-treat population only, using the approach
previously outlined [7].
Mean resource usage, costs, and their corresponding
standard errors (SE) by category were summarised for
each trial arm. Mean differences and 95% confidence
intervals (CIs) were calculated and compared through
two-sample t-tests.
EQ-5D utility index scores at each time point were
derived by mapping EQ-5D-5L responses to the EQ-5D-
3L tariff using the scoring algorithm of Van Hout et al.,
the method currently recommended by the National
Institute for Health and Care Excellence [17,18]. Dif-
ferences in the distribution of EQ-5D-5L responses
across the domains at each time point were compared
using Fisher’s exact test. Differences in mean EQ-5D
utility index scores at each time point between the two
arms were compared using the Wilcoxon signed-rank
test. Quality-adjusted life years (QALYs) for each pa-
tient were calculated using area under the curve after
linear interpolation between time points, with adjust-
ment for date of death where relevant. Finally, cumu-
lative mean QALYs over the follow-up period were
estimated with adjustment for baseline index score,
gender, and number of comorbidities at randomisation.
Neither resource use, costs, nor QALYs were
discounted.
Where patients had partially completed the RUQs, it
was assumed that resource use items left blank had not
been used within the relevant follow-up period.
Following best practice for the conduct of economic
evaluations alongside clinical trials, missing data from
partially completed EQ-5D-5L and fully incomplete
RUQs and EQ-5D-5L questionnaires were imputed
through multiple imputation by chained
equations under a missing-at-random assumption
[19,20]. Here, an imputation model is specified for each
incomplete variable. Missing entries are imputed in an
Table 1
Baseline characteristics of patients.
Variable Cisplatin
(N Z 166)
Cetuximab
(N Z 168)
Total
(N Z 334)
Age
Mean (SD) 57$54 (7$84) 57$46 (8$25) 57$50 (8$04)
Median
(IQR)
57$00 (10$10) 57$84 (12$30) 57$37 (10$93)
Gender
Male 132 (79$5%) 134 (79$8%) 266 (79$6%)
Female 34 (20$5%) 34 (20$2%) 68 (20$4%)
Tumour stage (TNM 7)
T1-T2 109 (65$7%) 107 (63$7%) 216 (64$7%)
T3-T4 57 (34$3%) 61 (36$3%) 118 (35$3%)
T4 only 32 (19$3%) 24 (14$3%) 56 (16$8%)
Nodal stage (TNM 7)
N0eN1 40 (24$1%) 41 (24$4%) 81 (24$3%)
N2eN3 126 (75$9%) 127 (75$6%) 253 (75$7%)
N3 only 1 (0$6%) 1 (0$6%) 2 (0$6%)
Primary subsite (N Z 329)
Base of
tongue
54 (32$9%) 58 (35$2%) 112 (34$0%)
Tonsil 107 (65$2%) 104 (63$0%) 211 (64$1%)
Other 3 (1$8%) 3 (1$8%) 6 (1$8%)
ECOG performance status (N Z 328)
0 142 (86$6%) 149 (90$9%) 291 (88$7%)
1 22 (13$4%) 15 (9$1%) 37 (11$3%)
Ever smoked? (N Z 329)
No 90 (54$9%) 85 (51$5%) 175 (53$2%)
Yes 74 (45$1%) 80 (48$5%) 154 (46$8%)
Planned PEG use before treatment
No 57 (34$3%) 58 (34$5%) 115 (34$4%)
Yes 109 (65$7%) 110 (65$5%) 219 (65$6%)
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tion models to converge at a value for each missing
entry, thereby avoiding dependence on the order in
which the variables are imputed. Missing values were
imputed separately by treatment arm, at the item level
for resource use and at the tariff level for EQ-5D-5L. All
missing variables were imputed using predictive mean
matching to allow for discrete target variables and
provide robustness against non-normality [21]. Predic-
tive mean matching ‘borrows’ values from the set of
observed data points with regression-predicted values
closest to the predicted value of the missing entry [22].
Covariates for each missing variable imputation
model included all other resource use and/or EQ-5D-5L
variables across all time points, as well as age, gender,
TNM stage, ECOG performance status, number of
comorbidities, and planned gastrostomy insertion
before treatment. A total of 20 sets of imputed values
were obtained. Rubin’s rule was used to generate com-
bined estimates of means and SEs across MI data sets
where appropriate [23]. Complete case analysis
restricted to the set of patients who had fully completed
questionnaires at each time point was also performed
for comparison, the results of which are available in the
online Appendix. Analysis of resource use, costs, and
HRQoL was performed using R version 3.5.1 [24].
Survival and recurrence rates were analysed in STATA
version 15.1 [25].3. Results
3.1. Study
A total of 334 patients were randomised between
November 2012 and October 2016, 166 to cisplatin and
168 to cetuximab, of whom 159 and 162, respectively,
made up the per-protocol population. Baseline charac-
teristics for patients in each arm of the trial are pre-
sented in Table 1. The groups were well balanced with
respect to demographic and clinical characteristics
including disease/symptom severity. In the following we
report the intention-to-treat results. Per-protocol results
can be found in the online Appendix.3.2. Overall survival and time to recurrence
Results from the recently published expedited results
paper showed no benefit from cetuximab in terms of
reduced overall severe and all-grade toxicity, and a sig-
nificant reduction in 2-year overall survival and recur-
rence [7]. The results of the updated intention-to-treat
analysis, with 2-year follow-up for all patients, again
showed a significant difference between cisplatin and
cetuximab in 2-year overall survival (97$5% vs 90$0%,
HR: 3.268 [95% CI 1$451 to 7$359], p Z 0$0251;
Fig. 1a) and in the 2-year recurrence rate (6$4% vs16$0%, HR: 2$67 [1$38 to 5$15]; p Z 0$0024; Fig. 1b),
in favour of cisplatin.3.3. Medical resource use and costs
Mean total resource use and costs over the trial follow-
up from the imputed data sets are presented in Table 2.
Patients in the cisplatin arm received on average 2$33
(SD: 0$70) cycles, including nine patients who switched
to carboplatin, while patients in the cetuximab arm
received 7$42 (SD 1$42). The greater number of cycles,
as specified in the protocol, and unit cost of cetuximab
relative to cisplatin led to a mean difference in total
treatment costs per patient of £7779 (95% CI: £7377 to
£8182) between the two arms. We found no statistically
significant differences in the mean number of hospital
inpatient days, day case/outpatient visits, accident and
emergency visits, or primary and community care con-
tacts between the two trial arms. Neither was there any
difference in associated mean costs for these categories.
Total costs after 24 months PT were £13517 (SE: £345,
equating to V14135 [SE: V361] using 2018 purchasing
price parities [26]) in the cisplatin group and £21064 (SE:
£400, V22027 [SE: V418]) in the cetuximab group.
Treatment with cetuximab therefore significantly
increased total cost per patient by on average £7547
Fig. 1. a: 2-year overall survival.b: 2-year time to recurrence.
Table 2
Medical resource use and costs.
Variable Cisplatin
(n Z 166) mean (SE)
Cetuximab
(n Z 168) Mean (SE)
Mean difference
(95% CI)
P-value
Medical resource use
Treatment cycles 2$33 (SD: 0$70) 7$42 (SD: 1$42)
Hospital inpatient stays (total days) 10$083 (1$081) 8$458 (1$078) 1$624 (4$62 to 1$371) 0$287
Hospital day/outpatient visits 15$311 (1$079) 15$523 (1$323) 0$211 (3$223 to 3$645) 0$903
Accident and emergency visits 0$395 (0$062) 0$556 (0$084) 0$161 (0$048 to 0$37) 0$131
Primary and community care contacts 24$802 (2$499) 24$916 (2$189) 0$113 (6$365 to 6$592) 0$973
Direct medical costs (£)
Treatmenta 7142$40 (90$94) 14921$86 (182$30) 7779$47 (7377$24 to 8181$70) 0$000
Hospital inpatient stays 2846$73 (236$42) 2553$18 (243$05) 293$54 (959$18 to 372$09) 0$386
Hospital day/outpatient visits 2485$66 (141$55) 2571$33 (175$29) 85$67 (347$78 to 519$12) 0$697
Accident and emergency visits 63$23 (9$94) 88$95 (13$48) 25$72 (7$72 to 59$17) 0$131
Primary and community care contacts 972$37 (105$58) 928$55 (85$26) 43$83 (309$38 to 221$73) 0$745
Total 13516$79 (345$43) 21063$88 (399$61) 7547$08 (6512$22 to 8581$95) 0$000
a Including study drugs, other medications received during the cycle, delivery costs, and radiotherapy.
Table 3
Unadjusted mean reported EQ-5D utility index scores.
Time point Cisplatin Cetuximab Utility
Difference
p-value
(ManneWhitney U test)
No$ Complete Mean (SD) No$ Complete Mean (SD)
Baseline 155 0$836 (0$147) 152 0$812 (0$153) 0$024 0$080
End of treatment 122 0$606 (0$223) 138 0$565 (0$231) 0$041 0$187
3 months post treatment 130 0$797 (0$145) 130 0$757 (0$173) 0$040 0$084
6 months post treatment 128 0$827 (0$153) 125 0$784 (0$176) 0$043 0$078
12 months post treatment 129 0$862 (0$144) 126 0$825 (0$194) 0$037 0$202
24 months post treatment 120 0$867 (0$139) 118 0$846 (0$144) 0$021 0$131
Fig. 2. Mean EQ-5D-5L utility index scores.
D.A. Jones et al. / European Journal of Cancer 124 (2020) 178e185182(95% CI: £6512 to £8582, V7892 [95% CI: V6810 to
V8974]).
3.4. Health-related quality of life
There was little difference in the distribution of EQ-5D-
5L responses across the domains (Appendix Table 6).
Baseline mobility was somewhat worse in the cetuximab
group with more patients reporting slight problems
rather than no problems. A similar outcome for self-care
at 3 months PT was found, although in favour of
cetuximab. There were statistically significant differ-
ences in the pain/discomfort domain at the end of
treatment, although with no clear monotonic trend, and
Table 4
Unadjusted and adjusted cumulative mean quality-adjusted life years (QALYs) from baseline.
Time point Cisplatin Cetuximab Mean difference (95% CI) P-value t-test
No$ Dead Mean (SE) No$ Dead Mean (SE)
4a: Unadjusted
End of treatment 0 0$120 (0$002) 1 0$114 (0$002) 0$006 (0$012 to 0$000) 0$058
3 months post treatment 1 0$294 (0$005) 2 0$278 (0$005) 0$016 (0$031 to 0$001) 0$031
6 months post treatment 3 0$494 (0$008) 5 0$466 (0$008) 0$028 (0$05 to 0$007) 0$011
12 months post treatment 4 0$904 (0$014) 7 0$849 (0$015) 0$055 (0$095 to 0$015) 0$007
24 months post treatment 4 1$740 (0$027) 17 1$612 (0$033) 0$128 (0$212 to 0$044) 0$003
4b: Adjusted
End of treatment 0$003 (0$008 to 0$001) 0$168
3 months post treatment 0$012 (0$025 to 0$002) 0$083
6 months post treatment 0$021 (0$041 to 0$002) 0$030
12 months post treatment 0$044 (0$080 to 0$007) 0$020
24 months post treatment 0$107 (0$186 to 0$029) 0$007
Fig. 3. Mean difference in cumulative QALYs. QALYs, quality-
adjusted life years.
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worse domain scores in the cetuximab arm.
The EQ-5D utility index score profile across time
(Table 3; Fig. 2) showed substantially lower mean
HRQoL levels at the end of treatment in both study
arms than at the baseline, which then recovered to at
least baseline levels by 12 months PT. No significant
differences between arms were detected at any time
point, although there was a non-negligible difference at
the baseline suggesting the need for adjustment in the
QALYs analysis.
Table 4 reports cumulative mean QALYs from the
baseline to 24 months PT, unadjusted (4a) and then
adjusted for baseline values (4b; Fig. 3). The unadjusted
results suggest a widening difference over time favouring
cisplatin, with a mean cumulative difference after
24 months PT of 0$128 QALYs in favour of cisplatin
(95% CI 0$212 to 0$044, p Z 0$003). Once adjusted for
the baseline EQ-5D-5L utility index score, gender, and
comorbidities, significant differences did not emerge
until the 6 months PT follow-up point and the mean
cumulative difference at 24 months was slightly lower
than the unadjusted result at 0$107 QALYs in favour of
cisplatin (95% CI: 0$186 to 0$029, p Z 0$007). Theseresults were driven primarily by the greater number of
deaths in the cetuximab arm.
4. Discussion
Expedited results of the De-ESCALaTE HPV trial
demonstrated the superiority of cisplatin over cetuximab
for tumour control in HPV-positive OPSCC patients.
Our completed 2-year overall survival and 2-year time-
to-recurrence analyses confirm the earlier findings.
Furthermore, our analysis of the comparative HRQoL
and health care costs confers additional support for the
superiority of cisplatin. Replacement of cisplatin with
cetuximab greatly increased the cost of treatment while
providing no statistically significant reduction in medi-
cal resource usage or their associated costs. Although,
patient-reported HRQoL as measured through the EQ-
5D utility index score was similar at each time point
among questionnaires returned, quality-adjusted sur-
vival was significantly lower in the cetuximab arm due to
the greater number of deaths. As such, cisplatin-based
chemoradiotherapy should continue to be considered
the standard of care in this setting.
The earlier results reported significantly higher
number of SAEs in the cisplatin arm compared with the
cetuximab arm, mainly due to the increased need for
hospital admission [7]. However, despite this, we found
no significant difference in the number of inpatient
hospital days or outpatient visits and their respective
related costs. This suggests that the SAEs may have been
less severe, each requiring shorter hospital stays on
average. Our results also highlight the drivers of
resource utilisation and costs associated with the dis-
ease. Of note, the cost of chemo/biotherapy and radio-
therapy was the single largest component, accounting
for over half of total costs per patient in both trial arms.
Finally, our results demonstrate not only the very high
rate of survival using cisplatin-based chemo-
radiotherapy in low-risk HPV-positive OPSCC patients,
but also the good HRQoL profile over time, with EQ-
D.A. Jones et al. / European Journal of Cancer 124 (2020) 178e1851845D utility index scores showing that on average patients
quickly rebound to the baseline HRQoL values after the
end of treatment, and with 24 month PT scores sur-
passing those at the baseline.
Together, these findings suggest a high bar for other
de-escalation strategies, especially those with anticipated
higher treatment-specific costs and fewer or less-severe
toxicities. Although the unexpected inferiority of
cetuximab combined with its higher cost precluded the
need for formal cost-effectiveness in this trial, the results
also demonstrate the importance of embedding health
economic components and analysis into future trials
investigating de-escalation strategies, to further aid
clinical decision-making.
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